<DOC>
	<DOCNO>NCT00786331</DOCNO>
	<brief_summary>The aim study compare time progression combination pemetrexed-carboplatin pemetrexed alone previously treat patient locally advance metastatic NSCLC .</brief_summary>
	<brief_title>Pemetrexed +/- Carboplatin Second Line Treatment NSCLC</brief_title>
	<detailed_description>In spite superiority single agent best supportive care second-line NSCLC , prognosis patient remain poor median survival 6-7 month , justify evaluation new regimen set . An open question second-line treatment NSCLC remain possible superiority combination chemotherapy single agent , clearly demonstrate first-line . Particularly , addition platinum either docetaxel pemetrexed investigate especially patient prior response/stable disease platinum-based first-line chemotherapy . Pemetrexed show anti-tumor activity combination chemotherapy agent , include gemcitabine , vinorelbine , taxanes , cisplatin carboplatin . In multicenter , open label , randomize phase II trial , pemetrexed 500 mg/m2 carboplatin AUC 5 administer day 1 every 3 week progression disease maximum 4 course experimental arm . The control arm pemetrexed single agent 500 mg/m2 day 1 every 3 week progression disease maximum 4 course .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>write informed consent Histologically cytologically confirm nonsmallcell lung cancer Unresectable stage IIIB , stage IV unresectable local relapse metastatic disease , evidence disease progression first line chemotherapy include platinum agent . ECOG performance status low equal 2 Adequate hematological , hepatic renal function Life expectancy great equal 12 week Prior treatment 1 chemotherapy regimen treatment advance disease include platinum agent At baseline , presence least one measurable target lesion per RECIST criterion Prior treatment pemetrexed . Patients pregnant lactate Patients underlie medical condition might aggravate treatment control . Symptomatic brain metastasis History another malignancy within past five year except basal cell carcinoma skin carcinoma situ cervix . Concomitant treatment anticancer drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>second line treatment</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>carboplatin</keyword>
</DOC>